No map available.
VCCC Breast Cancer Educational Series #15
Date: 11 May 2022
Time: 5:30pm – 6:30pm
Location: Zoom Webinar
Access level: Available to everyone
Email: [email protected]
“Yes, more NEW drugs in breast cancer (and it is not immunotherapy!)”
Date: Wednesday 11 May, 5:30pm – 6:30pm
How: ZOOM (you will receive the link when you register)
Leading experts will discuss the data regarding sacituzumab govitecan in triple negative breast cancer and both trastuzumab deruxtecan and tucatinib in HER2 amplified metastatic breast cancer.
Synopsis: There has been an overwhelming number of exciting trials in metastatic breast cancer in the last 5 years that have led to changing standard of care for our patients. The CDK 4/6 inhibitors are an obvious example in oestrogen receptor positive disease in combination with endocrine therapy. Whilst we hear a lot about immunotherapy, in Australia we are still waiting to be able to use this routinely (and in a funded manner) in a subset of patients that may benefit. The “new” kids on the block (so to speak) are the antibody drug conjugates (drugs like T-DM1) which have shown impressive survival benefits for patients in the advanced setting.
The guest speaker will discuss the data regarding sacituzumab govitecan in triple negative breast cancer and both trastuzumab deruxtecan and tucatinib in HER2 amplified metastatic breast cancer.
Please note do this before the day to ensure you have the details in time to log on.
- ASCENT - Conquering an uphill battle in advanced triple negative breast cancer?
Dr Iris Tung (Breast Fellow, Austin Health)
Iris Tung is the current Breast & GI Trials Fellow at Austin Health. She has previously trained at multiple cancer centres across metropolitan and regional Victoria. She has an interest in registry-based research in real-world outcomes for patients with breast and GI cancers.
- DESTINY is changing the treatment landscape in HER2+ breast cancer – an update on T-DXd and other novel antiHER2 therapies
Dr Julia Dixon-Douglas (Breast Trials Fellow, PMCC)
Julia Dixon-Douglas is the current Breast Trials Fellow at the Peter MacCallum Cancer Centre, having completed her final year of advanced training in 2021 as Melanoma and Early Drug Development Fellow at the Peter Mac. This has led to an active interest in clinical research with a particular focus on optimising immunotherapy (and other novel agents) in breast cancer.
Chair: Belinda Yeo
Panel for Discussion: Jim Siderov - Senior Pharmacist, Austin Health, Prof Bruce Mann - Director of Breast Cancer Services for the Royal Melbourne and Royal Women's hospitals
Any questions about registration or would like to unsubscribe from this mailing list, please email me [email protected]